Products
Antisoma focuses its activities on treatments for cancer, an area of significant unmet medical need.
Antisoma has a diverse portfolio of products in development. Our products target tumours by several different mechanisms and are intended for the treatment of a range of cancers.
AS1413 (amonafide L-malate)
A DNA intercalator in phase III in secondary AML
More on AS1413
AS1411
A DNA aptamer in phase II in AML
More on AS1411
ASA404 (DMXAA)
A Tumour-Vascular Disrupting Agent (Tumour-VDA) in phase III in second-line NSCLC
More on ASA404